ArticleCancer research and treatment2026

Clinical Relevance of Starting Alectinib at a Reduced Dose in Patients with ALK-Positive Non-Small Cell Lung Cancer.

Junkyu Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.